AXON


Axon Enterprise Reports Excellent Q3 Results; Shares Jump 22.5%

Shares of Arizona-based Axon Enterprise, Inc. (AXON) gained up to 22.

Axovant Sciences (AXON): Oppenheimer Dives into the Licensing Move That Has Wall Street Buzzing

Oppenheimer’s Jay Olson finds it encouraging to see AXON evolving its pipeline to gene therapy.

Here’s Why Axovant Sciences (AXON) Shares Rocketed 115% Today

It’s a very rewarding trading day for investors in Axovant Sciences (NASDAQ:AXON) with shares up nearly 115%, making the stock Wall Street’s bull …

Spooked Investors Send Axovant Sciences Ltd (AXON) Shares Spiraling; Here’s Why

Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …

Should You Give up on Genocea Biosciences Inc (GNCA), Axovant Sciences Ltd (AXON)? Analysts Dive In

A tale of two beaten biotech stocks: GNCA, AXON.

Here’s What Oppenheimer Has to Say About Axovant Sciences Ltd (AXON) Following Today’s Crash

Pivotal phase 3 MINDSET trial fails, AD program discontinued, Oppenheimer moves to sidelines.

Is It Time to Panic About Axovant Sciences Ltd (AXON) and Genocea Biosciences Inc (GNCA)? Analysts Weigh in

Healthcare analysts share two cents on two falling biotech stocks.

Axovant Sciences Ltd (AXON): What Just Happened To My Shares?

Axovant Sciences Ltd (NASDAQ:AXON) investors hit the panic button after the dementia drug maker announced that the Phase 3 MINDSET clinical trial of its investigational …

Oppenheimer’s Insights: Synaptics Incorporated (SYNA), Axovant Sciences Ltd (AXON), Syros Pharmaceuticals Inc (SYRS)

Synaptics Incorporated Top Oppenheimer analyst Andrew Uerkwitz has downgraded his rating on shares of Syros Pharmaceuticals Inc (NASDAQ:SYNA) to Sell – his first …

Evercore Comments on Axovant Sciences Ltd (AXON) Following Competitor’s Drug Setback

Axovant Sciences Ltd (NYSE:AXON) shares are falling nearly 12% following the news that Lundbeck’s experimental Alzheimer’s drug Idalopirdine failed in a late-stage study. …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts